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T he mechanism of hyponatremia is complex,  as it presents as a generalized hemodynamic derange-
ment [1].  Severe hyponatremia (serum sodium 
level < 125 mEq/L) is associated with serious sequelae,  
especially when the condition develops rapidly (within 
48 h) (e.g.,  confusion,  hallucinations,  seizures,  coma,  
and respiratory arrest,  leading to death) [2].  The syn-
drome of inappropriate antidiuretic hormone secretion 
(SIADH) is the most frequent cause of hyponatremia 
[3].  The criteria for diagnosing SIADH are as fol-
lows: euvolemic hyponatremia (serum sodium level 
< 135 mEq/L),  low serum osmolality ( < 275 mOsm/
kg),  urinary osmolality ( > 100 mOsm/kg),  natriuresis 
(urinary sodium level > 40 mEq/L),  normal thyroid,  
pituitary,  and adrenal function; and no recent use of 
diuretic agents [2 , 4 , 5].
The causes of SIADH include malignant diseases,  
pulmonary diseases,  disorders of the central nervous 
system,  and drugs such as chemotherapeutic and antie-
pileptic agents [2 , 6].  Symptomatic hyponatremia sec-
ondary to SIADH is extremely rare in recipients of liver 
transplantation; indeed,  only one previous case has 
been reported,  and hyponatremia developed as the ini-
tial presentation of cryptococcal meningitis after liver 
transplantation [7].
Here we describe the first reported case of a patient 
who developed drug-induced SIADH after undergoing 
a living donor liver transplantation (LDLT).
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Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an extremely rare cause of hyponatremia 
post-liver transplantation.  A 15-year-old Japanese girl with recurrent cholangitis after Kasai surgery for biliary 
atresia underwent successful living donor liver transplantation.  Peritonitis due to gastrointestinal perforation 
occurred.  Hyponatremia gradually developed but improved after hypertonic sodium treatment.  One month 
later,  severe hyponatremia rapidly recurred.  We considered the hyponatremia’s cause as SIADH.  We suspected 
that tacrolimus was the disease’s cause,  so we used cyclosporine instead,  plus hypertonic sodium plus water 
intake restriction,  which improved the hyponatremia.  Symptomatic hyponatremia manifested by SIADH is a 
rare,  serious complication post-liver transplantation.
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Case Report
A 15-year-old Japanese girl who had undergone 
Kasai surgery [8] for biliary atresia was referred to our 
facility for liver transplantation because of recurrent 
cholangitis.  Her laboratory data are shown in Table 1.  
The model for end-stage liver disease score was 12 points,  
and the Child-Pugh classification was B.
The patient underwent the LDLT at our facility with 
an extended left lobe graft donated by her mother.  The 
operative time was 7 h 36 min,  and the intraoperative 
blood loss was 1,090 mL without blood transfusion.  
The post-transplant immunosuppression treatment 
consisted of tacrolimus (TCL) and prednisolone.  She 
did not have any vascular complications or cellular 
rejection,  but she underwent surgical drainage for peri-
tonitis due to gastrointestinal perforation on days 13 
and 17 after the transplantation.
After a reoperation for the peritonitis,  she had diar-
rhea and clinical signs of excessive extracellular fluid 
retention,  including a weight gain of 7 kg compared to 
her preoperative weight and edema of the entire body.  
Subsequently,  her serum sodium concentration gradu-
ally decreased to 113 mEq/L (Table 1).  Her postopera-
tive clinical course is presented in Fig. 1.  An endocri-
nological examination showed a low serum osmolality 
level (226 mOsm/kg) and high urinary osmolality and 
sodium levels (507 mOsm/kg and 114 mEq/L,  respec-
tively).  The renal,  thyroid,  and adrenal findings were 
normal,  and the results of imaging studies including 
chest and abdominal computed tomography and brain 
magnetic resonance imaging showed no abnormality.
We considered that the overflow of fluids,  decrease 
in the sodium level due to diarrhea,  and use of diuretic 
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Table 1　 Laboratory values before liver transplantation and during the two episodes of hyponatremia
Reference value Before transplantation First episode of hyponatremia
Second episode 
of hyponatremia
WBC, /μL 3,300–8,600 4,130 5,920 3,150
Hb, g/dL  11.6–14.8 13.6 7.4 10.4
T-bil, mg/dL 0.40–1.50 4.3 0.88 1.15
D-bil, mg/dL 0.08–0.28 3.2 0.42 0.35
AST, U/L 13–30 95 35 16
T-Cho, mg/dL 142–248 166 93 188
TP, g/dL 6.6–8.1 7.2 4.5 5.1
Alb, g/dL 4.1–5.1 4.3 3.1 3.2
CRTN, mg/dL 0.46–0.79 0.7 0.26 0.33
BUN, mg/dL  8.0–20.0 9.4 4.4 1.1
UA, mg/dL 2.6–5.5 3.0 0.9 0.6
Na, mEq/L 138–145 139 113 109
K, mEq/L 3.6–4.8 4.5 4.0 3.1
CL, mEq/L 101–108 104 85 77
CRP, mg/dL <0.15 1.8 1.86 0.57
OSM, mOsm/kg 276–292 ‒ 226 223
U-OSM, mOsm/kg ‒ 507 521
U-Na, mEq/L 130–260 ‒ 114 80
AVP, pg/mL 0.0–4.2 ‒ 1.8 2.8
ACTH, pg/mL  7.2–63.3 ‒ 6.1 2.6
COR, μg/dL  8.0–25.0 ‒ 7.1 8.3
ALD, ng/dL  3.6–24.0 ‒ ‒ 4.6
Renin activity, ng/mL/h ‒ ‒ 0.4
TSH, μU/L 0.33–4.05 1.9 1.4 ‒
FT3, pg/mL 2.3–4.0 2.6 2.5 ‒
–,  No data.  ACTH,  adrenocorticotropic hormone; Alb,  albumin; ALD,  aldosterone; AST,  aspartate transaminase; AVP,  arginine vaso-
pressin; BUN,  blood urea nitrogen; CL,  chloride; COR,  cortisol; CRP,  C-reactive protein; CRTN,  creatinine; D-bil,  direct biliru-
bin; FT3,  free triiodothyronine; Hb,  hemoglobin; K,  potassium; LDH,  lactate dehydrogenase; Na,  sodium; OSM,  serum osmolali-
ty; T-bil,  total bilirubin; T-Cho,  total cholesterol; TP,  total protein; TSH,  thyroid stimulating hormone; UA,  uric acid; U-Na,  urinary 
sodium; U-OSM,  urinary osmolality; WBC,  white blood cell.  
agents significantly affected the hyponatremia,  and we 
therefore could not make a definitive diagnosis of 
SIADH.  The hyponatremia gradually improved within 
2 weeks after the administration of hypertonic sodium.  
She was discharged with a serum sodium concentration 
of 135 mEq/L on day 50 after the LDLT.
On day 78 after the LDLT,  the patient was readmit-
ted due to cholangitis with a serum sodium concentra-
tion of 140 mEq/L.  Fasting and the administration of an 
antimicrobial drug promptly resolved the cholan-
gitis; however,  severe hyponatremia (serum sodium 
level = 109 mEq/L) accompanied by malaise,  loss of 
appetite,  and headaches rapidly recurred on day 5 after 
readmission.  The endocrinological examination 
showed a low serum osmolality level with increased 
vasopressin suppression,  and high urinary osmolality 
and sodium levels (Table 1).  The levels of blood sugar 
and total cholesterol were normal,  which denied the 
possibility of pseudohyponatremia.
She had no clinical signs of excessive volume of 
extracellular fluid retention; thus,  we considered the 
cause of hyponatremia as SIADH.  Drugs were consid-
ered as possible factors in the etiology of SIADH,  
because the patient did not have ordinary causes of 
SIADH such as malignant disease,  pulmonary disease,  
and disorders of the central nervous system.  We sus-
pected that the TCL was the cause of the hyponatremia,  
so we used cyclosporine A (CyA) instead of TCL in 
addition to hypertonic sodium and a restriction of her 
water intake,  which improved the hyponatremia within 
2 weeks.
The patient has been followed up for 3 months with-
out a recurrence of hyponatremia due to SIADH after 
CyA was used instead of TCL.
Discussion
To our knowledge,  this is the first detailed descrip-
tion of a patient with hyponatremia due to drug-in-
duced SIADH following liver transplantation.  This case 
highlights the potential association between the admin-
istration of TCL and drug-induced SIADH and the 
importance of perioperative management,  including 
the diagnosis and treatment of SIADH.
Symptomatic hyponatremia secondary to SIADH is 
an extremely rare but occasionally life-threating com-
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Fig. 1　 Patientʼs clinical course after living donor liver transplantation (LDLT).  CyA,  cyclosporine A; Na,  serum sodium; PSL,  prednis-
olone; TCL,  tacrolimus.
plication in patients who have undergone liver trans-
plantation [7].  Our patient had two episodes of severe 
hyponatremia (Fig. 1).  Although data from the endo-
crinological examination met the criteria for SIADH 
during the first episode,  the presence of SIADH was 
masked by the clinical signs of an excessive volume of 
extracellular fluid,  including weight gain,  edema,  
pleural effusion,  and abdominal effusion,  and loss of 
sodium due to diarrhea and the administration of 
diuretic agents.  We considered the cause of hyponatre-
mia as the overflow of fluids and loss of sodium rather 
than SIADH.  During the second episode,  severe hypo-
natremia with symptoms rapidly developed despite the 
absence of the overflow of fluids,  and the criteria for 
SIADH were met.  Infections might be a trigger of 
SIADH,  but our patient’s cholangitis was not so severe 
and it was promptly resolved when the second episode 
of hyponatremia recurred.  The possibility of relative 
adrenal insufficiency might not be completely excluded,  
but it was not main pathophysiology in this case.  The 
immunosuppression management consisted of TCL and 
prednisolone (10 mg),  and we did not change the 
amount of prednisolone during the second episode 
(Table 1).  We checked the levels of cortisol and adre-
nocorticotropic hormone at the fastigium of the hypo-
natremia and the level of urinary free cortisol was also 
normal,  which denied relative adrenal insufficiency.
The etiology of SIADH varies and includes malig-
nant diseases,  pulmonary diseases,  disorders of the 
central nervous system,  and drugs [2 , 6].  Drug-
induced SIADH was considered the most plausible fac-
tor in the present case,  because the patient had no 
malignant diseases,  pulmonary diseases,  or disorders 
of the central nervous system.
Regarding drug-induced SIADH,  a variety of drugs 
can stimulate the release of arginine vasopressin or 
potentiate its action [2].  The hypothalamic production 
of vasopressin is increased by antiepileptic,  antipsy-
chotic,  and chemotherapeutic agents such as Vinca 
alkaloids,  platinum compounds,  and alkylating agents 
[2 , 6].  Drugs that cause SIADH change the normal 
osmoreceptor control of vasopressin secretion by direct 
toxic effects on the neurohypophysis and hypothalamic 
system [2 , 9].  TCL is a rare cause of drug-induced 
SIADH; indeed,  only three other cases have been 
reported [9-11].  In those three cases,  TCL was used as 
treatment for acute graft-versus-host disease [10],  sys-
temic lupus erythematosus [11],  and cord blood trans-
plantation [9],  and the TCL was stopped or decreased 
when the patient’s symptoms were suggestive of SIADH,  
which contributed to the improvement of hyponatre-
mia.
Although the definitive pathophysiology of TCL-
induced SIADH has not been examined,  we suspect 
that toxic effects on the neurohypophysis and hypothal-
amus occur [6 , 9].  In addition,  TCL can sensitize the 
kidneys to the antidiuretic hormone and stimulate the 
release of the antidiuretic hormone [10].  There were 
potential causative drugs of SIADH other than TCL in 
our patient’s case,  such as prednisolone,  fluconazole,  
and valacyclovir.  However,  the effects of these drugs 
were likely to be negligible,  because their administra-
tion was either decreased or stable at the onset of the 
SIADH.  There appear to be no previous reports evalu-
ating the relationship between SIADH and these drugs.  
We considered that TCL was the causative drug in our 
patient,  because there was a strong association between 
the occurrence of SIADH and the increase in blood 
concentrations of TCL.
The only definitive treatment of hyponatremia asso-
ciated with SIADH is the elimination of its causal 
lesions and the cessation of causative drugs [2 , 12].  For 
symptomatic patients with severe hyponatremia,  rapid 
treatment is warranted [5 , 13].  The goal is to increase 
the serum sodium level by 1 to 2 mEq/L/h by infusing 
3% saline.  During the first 24 h of treatment,  the cor-
rection should be no more than 8-10 mEq/L,  and 
during the first 48 h,  the correction should be no more 
than 18-25 mEq/L to avoid osmotic demyelination syn-
drome [2 , 5 , 14].  Avoiding overcorrection is particu-
larly important.  For asymptomatic patients,  hypona-
tremia should be corrected gradually by fluid 
restriction,  the intake of solute,  or the intake of salt.  
For our patient,  we used CyA instead of TCL and began 
sodium correction immediately by administering a 3% 
saline infusion.  During the first 24 and 48 h of treat-
ment,  the sodium level was corrected to 6 mEq/L and 
16 mEq/L,  respectively.  When a patient with SIADH is 
hospitalized,  physicians should avoid excessive infu-
sion,  closely monitor the sodium concentration in the 
serum and urine,  and prevent the occurrence of acute 
hyponatremia.
Despite our important findings,  there are a few lim-
itations to the present case report.  First,  the patho-
physiology of TCL-induced SIADH has not been iden-
tified in detail.  Second,  we diagnosed drug-induced 
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SIADH by elimination and considered that TCL was the 
most likely causative drug.  There were other potential 
causative drugs of SIADH,  but the patient’s hyponatre-
mia improved and has not recurred after CyA was used 
instead of TCL.
In conclusion,  our patient’s case may indicate that 
SIADH is a potentially important complication of hypo-
natremia following liver transplantation,  and this com-
plication should be kept in mind whenever TCL admin-
istration is performed,  irrespective of the dosage and 
TCL blood concentrations.
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